drugset / Trial / NCT03706053

Midodrine Use in Septic Shock

NCT03706053

Phase 3 Terminated 10 enrolled University of Virginia
RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.

Timeline

Start
2018-11-05
Primary completion
2022-02-11
Completion
2022-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Midodrine Small molecule 10 mg Other
Subject Midodrine Small molecule 20 mg Other